QLT delays Atrigel Phase IIa start

QLT (TSX:QLT; QLTI) said that it will delay the start of a Phase IIa trial of Atrigel octreotide to treat acromegaly after observing undisclosed adverse events in an ongoing primate toxicology study. The trial, which was expected to start next quarter, will be pushed back until after FDA reviews the complete primate results, which QLT plans to submit to the agency in December. ...